These results indicate that the use of CCT2 as a marker for CTCs is feasible with the current CTC technology, as exemplified by the CSS, and that in cancers like SCLC, could provide an additional discriminatory marker to improve enumeration as well as provide biological data that could be relevant to the invasive nature of the CTCs being detected. The gene discussed is CCT2; the disease is small cell lung carcinoma.